Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

2012 Scrip 100: Working the biosimilar boom

This article was originally published in Scrip

Executive Summary

As the next wave of patent cliff expirations erode into the balance sheets of the largest healthcare firms, biosimilar manufacturers will be handed huge opportunities. However, there are still many grey clouds hanging over the manufacture of biosimilars, both in terms of legislation and commercialisation. Maribel Rios of BioProcess International looks into this complex topic.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register